Adolescent hypertension. II. Characteristics and response to treatment.
D000293:Adolescent; D000328:Adult; D001741:Black or African American; D000804:Angiotensin II / Q000097:blood; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D007668:Kidney / Q000503:physiopathology; D007843:Latin America / Q000208:ethnology; D008297:Male; D008403:Mass Screening; D008750:Methyldopa / Q000627:therapeutic use; D009519:New York City; D011433:Propranolol / Q000627:therapeutic use; D011863:Radioimmunoassay; D012083:Renin / Q000097:blood; D012964:Sodium / Q000652:urine; D013148:Spironolactone / Q000627:therapeutic use
D000804:Angiotensin II; D006830:Hydralazine; D013148:Spironolactone; D008750:Methyldopa; D012964:Sodium; D011433:Propranolol; D012083:Renin